CAMP · Camp4 Therapeutics Corp
$3.19
+0.18 (+5.98%)
At close · Jul 24
Market Cap
$164.09M
Shares
51.93M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.5M
+436.5%
FY2025
Net Income
-$80.4M
-55.2%
FY2025
Operating Margin
-1502.43%
+6639.9pp
FY2025
Diluted EPS
-$2.65
+76%
FY2025
Operating Cash Flow
-$29.55M
+35.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $3.93M | $3.5M | $652K | $350K | |
| $38.22M | $38.2M | $38.82M | $40.62M | |
| $17.75M | $17.36M | $14.92M | $11.61M | |
| $1.74M | $1.64M | $1.7M | $1.68M | |
| $56.46M | $56.05M | $53.74M | $52.23M | |
| -$52.53M | -$52.56M | -$53.09M | -$51.88M | |
| — | -1502.43% | -8142.33% | -14822.57% | |
| -$50.79M | -$50.92M | -$51.39M | -$50.2M | |
| $2.5M | $2.17M | $1.33M | $2.81M | |
| -$33.78M | -$27.85M | $1.3M | $2.59M | |
| $0 | $0 | $0 | $0 | |
| -$86.3M | -$80.4M | -$51.79M | -$49.29M | |
| — | -2298.54% | -7943.4% | -14083.14% | |
| — | -$80.4M | -$51.79M | — | |
| -$86.3M | -$80.4M | -$51.79M | -$49.29M | |
| USD/shares | — | -$2.65 | -$11.04 | -$124.80 |
| USD/shares | — | -$2.65 | -$11.04 | -$124.80 |
| shares | — | 30.38M | 4.69M | 394.98K |
| shares | — | 30.38M | 4.69M | 394.98K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
—
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| RD | $3,498,000 | $652,000 | $350,000 |